E
Spyre Therapeutics, Inc. SYRE
$28.40 -$0.26-0.91% NASDAQ
Recommendation
Prev Close
$28.40
Volume
643,630
Avg Vol (90D)
758,716
Market Cap
$2.20B
Dividend & Yield
--
52-Week Range
$10.91 - $30.55
P/E (TTM)
--
EPS (TTM)
-$1.20
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Spyre Therapeutics (SYRE, $28.66) RSI Indicator left the overbought zone on December 01, 2025
12/2/2025 - Tickeron - Stocks
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High on Analyst Upgrade
12/2/2025 - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to Buy Rating
12/2/2025 - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High on Analyst Upgrade
12/1/2025 - Ticker Report
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to Buy Rating
12/1/2025 - Ticker Report
Spyre Therapeutics just upgraded at JonesResearch, here's why
12/1/2025 - The Fly
Spyre Therapeutics, Inc. $SYRE Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH
11/27/2025 - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week High - Here's What Happened
11/26/2025 - MarketBeat
Foresite Capital Management VI LLC Makes New Investment in Spyre Therapeutics, Inc. $SYRE
11/26/2025 - MarketBeat
Spyre Therapeutics (SYRE, $26.97) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 24, 2025
11/25/2025 - Tickeron - Stocks
Spyre Therapeutics (SYRE, $26.97) price may drop as it broke higher Bollinger Band on Nov 24, 2025
11/25/2025 - Tickeron - Stocks
Spyre Therapeutics (SYRE, $26.97) RSI Indicator left the overbought zone on November 24, 2025
11/25/2025 - Tickeron - Stocks
Jefferies Financial Group Inc. Has $20.79 Million Stake in Spyre Therapeutics, Inc. $SYRE
11/25/2025 - MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from Brokerages
11/19/2025 - MarketBeat
Spyre Therapeutics (SYRE, $24.36) entered Uptrend as Momentum indicator ascends above 0 level on Nov 17, 2025
11/18/2025 - Tickeron - Stocks
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003
11/17/2025 - Insider Monkey
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003
11/17/2025 - Yahoo! Finance: News
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Wall Street Zen to Hold Rating
11/16/2025 - MarketBeat
Spyre Therapeutics (SYRE): Evaluating Valuation Following Encouraging SPY003 Trial Results and Improved Financials
11/16/2025 - Simply Wall St
Will Positive Phase 1 SPY003 Data and Narrowed Losses Reshape Spyre Therapeutics' (SYRE) Narrative?
11/13/2025 - Simply Wall St
Spyre Therapeutics (SYRE, $23.35) Stochastic Oscillator left the oversold zone on November 11, 2025
11/12/2025 - Tickeron - Technical Analysis
Analysts Expect OPTZ Will Reach $43
11/10/2025 - ETF Channel
Assessing Spyre Therapeutics (SYRE) Valuation After Recent Share Price Rebound
11/9/2025 - Simply Wall St
FY2025 Earnings Estimate for SYRE Issued By Leerink Partnrs
11/8/2025 - MarketBeat
Spyre Therapeutics (SYRE, $22.52) entered Downtrend as Momentum indicator drops below 0 level on Nov 07, 2025
11/8/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$61.07M
EBIT (TTM)
-$223.64M
Net Income (TTM)
-$148.97M
Balance Sheet
Total Assets (Q)
$504.60M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$49.50M
Book Value Per Share (Q)
$4.95
Cash Flow
Cash from Operations (TTM)
-$161.87M
Cash from Investing (TTM)
-$66.61M
Cash from Financing (TTM)
$221.81M
Net Change in Cash (TTM)
-$6.68M
Filings
Filing Date
Tuesday, November 4, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.40
7-Day Total Return
17.07%
30-Day Total Return
22.15%
60-Day Total Return
69.65%
90-Day Total Return
67.26%
Year to Date Total Return
19.08%
1-Year Total Return
4.14%
2-Year Total Return
47.23%
3-Year Total Return
141.39%
5-Year Total Return
-86.20%
52-week Low
Apr 09, 2025 - $10.91
52-week High
Dec 01, 2025 - $30.55
Valuation
Market Cap
$2.20B - Mid Cap
Enterprise Value
$1.87B
Price/Sales (TTM)
--
Price/Book (Q)
5.74
Dividends and Shares
Shares Outstanding
60.41
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.spyre.com
Phone Number
617 651 5940
Address
221 Crescent Street
Building 23 - Suite 105
Waltham, MA 02453
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed